The most commonly used immune checkpoint blockade agents target PD‐1, PD‐L1, CTLA‐4, etc[37] although their use as monotherapeutic agents is usually associated with low response rates.[39] Therefore, the combination of multiple immune checkpoint inhibitors or the inclusion of other non‐cross‐resistant agents has become a new standard for HCC. The gene discussed is CTLA4; the disease is hepatocellular carcinoma.